A systematic review of the spectrum of magnetic resonance imaging features of degenerative thoracic myelopathy.

Neurosurg RevOct 26, 2026 (epub)

Eleanor White, Amir Rafati Fard, Jay Wardropper et al.

✦ AI-curated · Sources linked

In 30 seconds

This PRISMA-guided systematic review synthesised evidence on MRI features of degenerative thoracic myelopathy (DTM) and their clinical significance. It included 59 studies of 2,940 patients: one cross-sectional study and 58 cohort studies, with qualitative synthesis. Ossification of the ligamentum flavum was the most frequently reported pathology (71.4%, 2065/2893), compared with intervertebral disc herniation (20.1%, 582/2893) and ossification of the posterior longitudinal ligament (19.7%, 569/2893). Spinal canal compromise, cord signal change, ligamentous ossification and multilevel disease were associated with greater severity and poorer functional recovery.

Key findings

  • DTM was most common in the lower thoracic spine (62.5%, 880/1409).
  • Ossification of the ligamentum flavum was reported in 71.4% (2065/2893), more often than disc herniation (20.1%, 582/2893).
  • Spinal canal compromise was described in 55.5% (1631/2940) of patients and spinal cord signal change in 30.0% (881/2940).
  • Canal compromise, cord signal change, OLF, OPLL and multilevel disease were associated with greater severity and poorer functional recovery.

Why it matters

The review brings together MRI findings across a broad DTM literature and highlights that ligamentous pathology is more prevalent than disc-related disease in the included studies. It also identifies imaging features associated with severity and recovery, helping frame MRI interpretation in relation to clinical outcomes. Variation in terminology and study design limits comparisons and points to a need for more consistent reporting.

What to keep in mind

The evidence was predominantly observational: 58 of 59 included studies were cohort studies. The review used qualitative synthesis, and the authors call for standardised imaging terminology and study design.

Source

Published in Neurosurg Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Radiology (Diagnostic)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.